ZTS

Executive Summary

Broken compounder or cyclical trough in a two-horse race?

Zoetis is a former compounder trading like a value stock: $73.59, down 51.6% from its 52-week high, at 11.9× forward earnings, on a franchise that still prints 72.9% adjusted gross margin, a 38% operating margin and about $2.3B of trailing free cash flow. The bear case is real. Key dermatology fell 16% to $395M in Q2 with US in-clinic share down 10 points to roughly 86%, Librela US fell 24% to $34M, US companion animal dropped 11%, and Elanco's Zenrelia and Credelio Quattro are taking share while Cerenia and Convenia face generics. Guidance was cut twice in six months to $6.15–$6.25 adjusted EPS on organic revenue of −3% to −1%, and H1 buybacks of $1.19B outran H1 free cash flow of $0.83B (SEC EDGAR). The bull case is that this is a trough, not a break: International grew 6%, Livestock 11%, Simparica Trio international +34%, long-acting Cytopoint is expected in the US later in 2026, and a CKD antibody targets a $3–4B market from 2027. Management concedes the competitive reset could take 6 to 18 months, and a securities class action is pending. At this multiple the debate is the duration of erosion, not the existence of the moat. Three directors bought after the May crash and nobody has sold. We initiate at BUY with a $86 target and Medium conviction, built in tranches — the first is small, because the next hard datapoint is a Q3 print that could bring a third cut.

By the numbers

Value-stock multiple, growth-stock margins — ZTS at $73.59 (Yahoo Finance, Sep 9, 2026). Revenue, EPS, cash and debt from the Q2 FY26 10-Q via SEC EDGAR; margins and TTM ratios from the Q2 release and StockAnalysis, Sep 9, 2026. Net debt and enterprise value are COMPUTED.

Share price

$73.59

−51.6% from 52w high · 50-DMA $75.53 · 200-DMA $102.60 · RSI(14) 42.6

Forward P/E

11.9×

Consensus FY26 EPS $6.21, FY27 $6.53 · EV/EBITDA 9.4× (StockAnalysis)

FY26 revenue guide

$9.12–9.32B

Organic −3% to −1% · cut from $9.68–9.96B on Aug 6 (company-stated)

Q2 FY26 revenue

$2.468B

Flat reported, −1% organic · US −7%, International +6% (10-Q, SEC EDGAR)

Q2 diluted EPS

$1.65

GAAP, +1% YoY (10-Q) · adjusted $1.87, +5% (company-stated)

Adj. gross margin

72.9%

Q2 FY26, −40 bps YoY · FY26 COGS guided at about 29% of revenue

Operating margin

38.1%

TTM (StockAnalysis) · adj. net margin 31.6% in Q2 ($781M on $2.468B, COMPUTED)

Net debt / EV

$7.7B / $38.1B

COMPUTED: $9.15B debt less $1.48B cash at Jun 30 (10-Q) · $750M due within 12 months · 2.9% dividend yield · H1 buybacks $1.19B vs H1 FCF $0.83B

Quarterly Revenue — SEC EDGAR (10-Q / 10-K)

$2.40B

Q3 FY25

$2.40B

Q4 FY25

$2.26B

Q1 FY26

$2.47B

Q2 FY26

Growth story

Two franchises eroding, one pipeline that has to deliver

$395M · −16%

Key dermatology, Q2 FY26

Apoquel plus Cytopoint; US $251M, −18%, in-clinic share about 86% (−10 pts YoY). Elanco's Zenrelia is now a blockbuster in about 18,000 US clinics. Long-acting Cytopoint, US approval expected later in 2026, is the reply.

$147M · −3%

OA pain mAbs (Librela, Solensia), Q2 FY26

Librela US $34M, −24%; feline +12%. A post-label-update trust hit in the US, but the 3-month Lenivia and Portela formulations are launching in the EU, Canada and GB. The securities class action covers Librela disclosures.

$731M · +11%

Livestock, Q2 FY26

US +23% on cattle economics and New World screwworm demand (Dectomax-CA1 conditional approval). Management flags part of this as transitory; normalised growth is mid-to-high single digit. International total +6%.

Sep 14, 2026

Morgan Stanley Global Healthcare Conference

CEO Kristin Peck and new CFO/COO Jay Saccaro fireside chat, 1:50pm ET. First public read on Saccaro's capital-allocation and cost stance after his Aug 17 start, and the last management commentary before the Q3 quiet period.

H2 2026

Long-acting Cytopoint US approval

A 3-month injectable intended to re-anchor dermatology in the clinic against Zenrelia and price discounting. Also expected: next-generation chemistry diagnostics and the HVT-ND poultry vaccine (company-stated pipeline).

Early Nov 2026

Q3 FY26 earnings

The test of whether derm share stabilises near 86% and whether US Librela finds a floor. Consensus Q3 EPS about $1.51–$1.53 on about $2.31B revenue. Watch the buyback pace ($1.3B left on the $6B authorisation at Jun 30) and any Q4 run-rate commentary. A third guidance cut breaks the trough thesis.

Feb 2027

FY26 results and FY27 guide

Street FY27 EPS of $6.53 implies a return to growth. Peck has said the competitive reset could take 6, 12 or 18 months. The FY27 guide is either the re-rating catalyst or the second leg down; our base case sits below the Street at about $6.30.

2027

CKD monoclonal antibody

First therapy for early renal disease in dogs and cats; management cites a $3–4B addressable market. Part of a pipeline management describes as holding 12-plus blockbuster candidates (oncology, cardiology, anxiety, obesity).

Earnings & Signals

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

FY+1 EPS Consensus$6.21 (FY26 consensus, −3.2% YoY; company guide $6.15–$6.25)

FY+2 EPS Consensus$6.53 (FY27 consensus, +5.2%) — our base case uses $6.30

PEG Ratio2.20 (StockAnalysis) — not meaningful while the growth rate is negative

Forward P/E11.9× ($73.59 / $6.21)

EPS Revisions (90d)↑0 reported ↓12 analysts revised down (InvestingPro, Aug 20, 2026) (Sharply negative — FY26 consensus tracked the Aug 6 cut lower; PTs cut by Stifel, TD Cowen, Citi, BNP Paribas Exane, Morgan Stanley and JPMorgan in Aug 2026)

Guidance AccuracyPoor — the FY26 adjusted EPS guide went $7.00–$7.10 (Feb 12) to $6.85–$7.00 (May 7) to $6.15–$6.25 (Aug 6), a roughly 12% midpoint cut in six months; the revenue guide fell from $9.83–$10.03B to $9.12–$9.32B (organic −3% to −1%). Both cuts were driven by dermatology share loss, Simparica Trio discounting and Librela weakness.

Earnings Surprise Track Record

Q3 FY25 (Nov 4, 2025) Est: $1.62 Act: $1.70 +4.9%

Q4 FY25 (Feb 12, 2026) Est: $1.40 Act: $1.48 +5.7%

Q1 FY26 (May 7, 2026) Est: $1.62 Act: $1.53 −5.6%

Q2 FY26 (Aug 6, 2026) Est: $1.86 Act: $1.87 +0.5%

Beat Rate3 of 4 (75%) on adjusted EPS — but the beats are buyback-assisted, each of the last two prints came with a guidance cut, and Q1 and Q2 revenue both missed. GAAP diluted EPS per SEC EDGAR: $1.63, $1.42, $1.42, $1.65.

Insider Activity (90 Days)

Net Buying/Selling$0 open-market in the last 90 days. Last buys May 11–13, 2026, about 120 days ago (Form 4s, SEC EDGAR)

Sell/Buy Ratio0 sells : 3 buys — all 12 Form 4s filed since May 1, 2026 were read from EDGAR; none is an open-market sale

Mildly positive but stale. Three directors bought after the May 7 crash — Michael McCallister 3,000 shares at $77.76 (May 11), Frank D'Amelio 6,650 at $75.39 (May 13), Paul Bisaro 2,000 at $75.88 (May 13), about $886K in total — and nobody has sold. But no officer or director bought after the Aug 6 second guidance cut or at the late-Aug $71 low, and insiders own only 0.22%. A pre-drop tax-withholding Form 4 priced at $114.97 on Apr 30 shows where the stock stood a week before May 7.

D'Amelio gifted 6,650 shares on Aug 7, 2026 (Form 4, $0, the same count he bought in May; 14,808 held after). New CFO/COO Jay Saccaro filed a Form 3 on Aug 24 and a derivative-only Form 4 on Sep 2 (sign-on RSU grant, not a purchase). The Jul 14 batch of nine Form 4s is annual executive equity grants. Congressional trades: Rep. Ro Khanna made small ($1–15K) buys and sells May–Aug 2026, last a buy at $77.13 on Aug 3.

Peer Comparison

Relative Valuation vs. Competitors

Company	P/E (fwd)	EV/Rev	Rev Growth	Gross Margin
Zoetis	11.9×	4.0×	0% (Q2, −1% org.)	71.7%
Elanco	19.8×	3.1×	+10% (Q2, +8% org.)	55.4%
IDEXX	33.2×	9.2×	+10% (Q2, +9% org.)	62.5%
Merck (Animal Health parent)	17.1×	6.2×	+8% (AH Q2, +5% ex-FX)	75.9%

Multiples from StockAnalysis statistics pages as of Sep 9, 2026 (ZTS EV $38.0B on $9.53B TTM revenue; ELAN EV $15.65B; IDXX EV $41.9B; MRK EV $411B, whole company, so its P/E and EV/Rev are not like-for-like). Revenue growth is Q2 FY26 reported from each company's release; the Merck figure is its Animal Health segment ($1.775B, Bravecto $359M +7%). ZTS is the only one shrinking and the only one below 12× forward, while carrying the best margins in the group after Merck's consolidated pharma mix. Elanco's premium reflects Zenrelia and Credelio Quattro momentum and a raised FY26 guide.

FAIR VALUE

Priced for permanent decline; worth about $87 if earnings merely stop falling — independent of where the stock trades

Method	Implied Value / Share	Weight	Basis
P/E on trough earnings	$88	40%	Our FY27 EPS of $6.30 (flat to slightly up on the $6.15–$6.25 FY26 guide, below the $6.53 Street figure) × 14×. That multiple is less than half Zoetis's roughly 30× ten-year average and below Elanco's 19.8×, which is what a share-losing derm franchise and an unsettled Apoquel patent date deserve until the FY27 guide proves otherwise.
EV / EBITDA	$89	30%	TTM operating income of about $3.6B (38.1% on $9.53B TTM revenue, StockAnalysis) plus about $0.5B D&A gives EBITDA of roughly $4.1B, COMPUTED. At 11× (vs 9.4× today and a mid-teens history) EV is $45B; less $7.7B net debt over 417.7M diluted shares (Q2 10-Q) = $89.
Free-cash-flow yield	$85	30%	TTM FCF of about $2.3B capitalised at a 6.5% yield (today's is about 7.5%) = $35.4B of equity, or $85 per diluted share. This is the floor method: it needs no growth, only that cash generation holds near current levels.
Blended estimate	$87	100%	+18% vs. the $73.59 market price — three methods land within $4 of each other

Reading it

All three methods say the same thing: at $73.59 the market is capitalising Zoetis as a business in structural decline, and it only takes earnings holding flat for the stock to be worth the mid-to-high $80s. The methods deliberately use multiples far below the company's own history, because the derm share loss and the Apoquel patent question (2030 per the compound patent, about 2032 per management, no date in the 10-K) are real. What the valuation does not protect against is a third guidance cut, which is why the position is built in tranches rather than bought outright.

Shared inputs

Diluted shares417.7M weighted, Q2 FY26 (10-Q); 413.2M issued at Jul 31, 2026 (cover page). Market cap $30.4B on issued, $30.7B on diluted — COMPUTED

Net debt$7.7B COMPUTED: $9.15B debt carrying amount less $1.48B cash at Jun 30, 2026 (10-Q). Cash fell from $2.45B at Dec 31 as buybacks ($1.19B in H1) exceeded FCF ($0.83B in H1)

Enterprise value$38.1B COMPUTED at $73.59 — about 4.0× TTM revenue

FY27 EPS used$6.30 (our estimate) vs $6.53 consensus and the $6.15–$6.25 FY26 guide

Valuation

Price Targets & Scenarios

Scenario	Price Target	Assumptions	Probability
Trough confirmed, growth returns	$116	Derm share stabilises near 85% as long-acting Cytopoint lands, US Librela bottoms, and the Feb 2027 guide calls for 4–6% organic growth. FY27 EPS about $6.80 × 17× — still barely half the historical multiple. Buyback continues at roughly $2B a year.	20%
Flat earnings, multiple partly rebuilds	$88	FY26 lands inside the $6.15–$6.25 guide, FY27 EPS about $6.30 (below the $6.53 Street). Derm keeps sliding but more slowly; livestock normalises; international carries the top line at low single digits. 14× on stabilised earnings, cross-checked at 11× EV/EBITDA.	50%
Third cut, structural reset	$62	Q3 or the FY27 guide brings another cut: derm share falls toward 80%, Simparica Trio pricing breaks, and Apoquel generic timing is pulled forward to 2030. FY27 EPS about $5.60 × 11×. Buybacks slow to protect the balance sheet with $750M of debt due within a year.	30%

Probability-Weighted Target: $86 (+17% vs. $73.59)

$86

Weighted

Bull $11620%

Base $8850%

Bear $6230%

Analyst Consensus

Stifel

$80

Cut PT to $80 from $85, Hold (Aug 20, 2026) — Key Franchise volume −3% YoY, price realisation decelerating

TD Cowen

$94

Cut PT to $94 from $104, Buy maintained (Aug 25, 2026)

Citigroup

$96

Cut PT to $96 from $112, Buy maintained (Aug 11, 2026)

Morgan Stanley

$85

Cut PT to $85 from $99, Overweight maintained (Aug 7, 2026, post-Q2)

8 Buy · 9 Hold · 2 Sell — Consensus is Hold across 19 analysts (MarketBeat) with a $101 average target that is stale: every post-Q2 action has been a cut, targets now cluster $80–$96, and William Blair downgraded to Market Perform in Aug 2026. StockAnalysis shows a friendlier 9 Buy / 9 Hold / 0 Sell with a $96 average.

Technical

Key Levels & Options Intelligence

S/RSupport & Resistance

52-week high (Sep 2025)

$152.00

May 7 gap top (May 6 close)

$111.22

200-DMA

$102.60

May 7 crash close (−21.5% day)

$87.31

Resistance — broken $77 support (Investtech, Sep 8)

$77.00–77.60

50-DMA

$75.53

Current price

$73.59

Near support (Investtech, Sep 8)

$73.28

52-week low (late Aug 2026; $71.41 close)

$71.00

OptOptions & Sentiment

Short interest: 16.78M shares · 4.07% of float · settlement Aug 14, 2026 (MarketBeat)
Days to cover: 2.0 days
Short-interest change: −21.4% vs Jul 31, 2026 — shorts covered into the Aug 6 print
Put/call ratio: 0.92 volume · 0.92 open interest (AlphaQuery, Sep 8, 2026)
Implied volatility (30d): 37.1% mean (calls 38.4%, puts 35.8%) vs 35.1% realised — IV at realised, no fear premium; IV rank not sourced
Upcoming expiries: Sep 18, 2026 · Oct 16 · Dec 18 · Jan 15, 2027 · Mar/Apr/Jun 2027 LEAPs
Notable flow: Not sourced
Beta: 0.73 (StockAnalysis) — defensive by history, not by 2026 behaviour

Conviction Analysis

Systematic Conviction Score: 52/100 (Medium)

Analyst Alignment

30%

FCF Visibility

25%

Catalyst Clarity

20%

Valuation Safety

15%

Mgmt Quality

10%

Weighted 0.30 analyst, 0.25 FCF, 0.20 catalyst, 0.15 valuation, 0.10 management. Analyst alignment 50: 8 Buy / 9 Hold / 2 Sell and targets of $80–$96 imply upside, but every August action was a cut and the Street is Hold-leaning rather than capitulated. FCF visibility 60: about $2.3B TTM on a $30B cap is a real 7.5% yield, but two guide cuts in six months mean FY26 and FY27 cash flow is being re-based lower, not confirmed, and H1 buybacks outran H1 FCF. Catalyst clarity 40: no dated positive catalyst; the screwworm authorisation is small, the Apoquel patent date is contested, and the next hard datapoint is a Q3 print that could bring a third cut. Valuation safety 68: 11.9× forward against a roughly 30× history, a 2.9% dividend and three methods that agree on the high $80s, capped by $7.7B of net debt and falling US companion-animal revenue. Management 35: two guidance cuts, a −21.5% day, a securities class action about disclosure, and a combined CFO/COO seat; directors bought in May, but nobody stepped in after Aug 6. The total of 52 is Medium: the value is clear, the timing is not.

Risk & Ownership

Risk Assessment & Insider Signals

OOwnership & Insider Signals

Institutional ownership about 92.8%: 1,899 institutions holding about 445.4M shares per 13D/G and 13F filings (Fintel). Trailing-12-month flow: 977 buyers ($16.68B) vs 994 sellers ($7.69B) per MarketBeat.
Top holders — Vanguard 10.8%, BlackRock about 16% across two entities: Vanguard 47.78M shares (10.79%), BlackRock Funding 37.35M (8.43%), BlackRock Inc 36.84M (8.04%); together 27.3% (Fintel). Next tier: J. Stern and Co, State Street, State Farm, Morgan Stanley, Wellington (about 9.4M, 2.28%), Geode, Vanguard Dividend Growth, Norges Bank.
Insider ownership 0.22%: Per MarketBeat. Negligible skin in the game; the May 2026 director buys (about $886K) are the only open-market insider purchases on record in 12 months, and none followed the Aug 6 cut or the late-Aug low.
Michael Burry / Scion long — size not sourced: Burry disclosed via Substack (per Insider Monkey, Aug 18, 2026) that he has increased a ZTS stake, arguing it trades at a discount to Elanco despite stronger FCF conversion and roughly twice the R&D spend. Share count and portfolio weight were not found in any 13F-derived source.
2026 13F moves — mixed: Fintel: Morningstar Investment Management cut its stake by nearly half while Vanguard and other large holders added. MarketBeat: HighTower Advisors −39.7% to 253K shares (Aug 26 filing). MarketBeat's CalSTRS 47.7M-share row conflicts with Fintel's Vanguard figure and looks like a data error, so it was not relied on.
Short interest low: 4.07% of float, 2.0 days to cover, down 21.4% into the Aug print (MarketBeat). This is not a crowded short; the selling has been long-only de-rating, which also means there is no squeeze fuel.

Risk Heatmap

Quantified Risk Assessment

Severity Risk Factor Prob. PT Impact

High Dermatology erosion — Zenrelia now, Apoquel patent cliff unsettled

Q2 derm −16% to $395M; US in-clinic share −10 pts to about 86% as Elanco's cheaper Zenrelia takes share. Apoquel is about 12% of revenue and its patent timing CONFLICTS across sources: vendor blogs say 2026, Pharsight lists compound patent US8133899 expiring Apr 9, 2030, and management said on the Q4 FY25 call that protection extends to approximately 2032. The FY2025 10-K gives no date. Treat it as 2030–2032, not a fact.

70% -15%

High Guidance credibility and a third cut

FY26 adjusted EPS guide cut twice in six months, $7.00–$7.10 to $6.85–$7.00 to $6.15–$6.25, with a −21.5% day on May 7. Jay Saccaro now holds both the CFO and COO seats. William Blair downgraded; Stifel and UBS cut to $80. A third cut at the Q3 print or in the Feb 2027 guide breaks the trough thesis and our base case.

35% -12%

Medium Librela safety overhang and litigation

FDA holds more than 3,800 adverse-event reports (ataxia in about 17% of 3,674 cases, seizures, paresis, deaths); the label was updated for neurological and mobility events and Librela US fell 24% in Q2. A New Jersey federal court dismissed the consumer class action in Jul 2026, but the securities class action (class period Jan 14, 2025 to May 6, 2026) is proceeding past the lead-plaintiff stage.

50% -8%

Medium Parasiticide pricing pressure on Simparica Trio

Trio passed $1B of US sales in 2025, but Credelio Quattro (lower price, faster tick kill per Elanco's Jul 2026 study) and Bravecto Quantum are redistributing rather than expanding the market. The CEO cited a more price-sensitive environment and more promotional activity. The Aug 13 FDA emergency authorisation of Trio against screwworm is treatment-only and limited to Texas and New Mexico.

60% -7%

Medium Leverage and buyback sustainability

Net debt about $7.7B against TTM FCF of about $2.3B, with $750M of principal due within 12 months and $1.35B the year after (Q2 10-Q). H1 buybacks of $1.19B exceeded H1 FCF of $0.83B and cash fell $974M in the half. The buyback is worth roughly $0.22 of FY26 EPS; if it slows, adjusted EPS growth goes with it.

45% -6%

Medium Livestock normalisation and vet-visit macro

Livestock +11% in Q2 is partly screwworm-driven and, by management's own words, partly transitory, so FY27 comparisons get harder just as the buyback tailwind fades. US vet visits fell 3.1% in 2025, a fourth straight annual decline (Vetsource), and IDEXX guides about −2% for 2026 as clinic prices rise 5–8% a year.

55% -5%

Recommendation

Summary

Rating

BUY

Conviction

Medium

Price Target

$86

Timeframe

12–18 months — the FY27 guide in Feb 2027 is the decision point

Upside

+17%

Position Size

2–3% of portfolio at full build (tranche 1 ≈ 1%) · dividend covers part of the wait

Entry Strategy

Tranche 1 — 40%

$74 or below (now)

Initiate at the 52-week low zone, below the 50-DMA and the $77 broken support. This is the valuation tranche: 11.9× forward, 7.5% FCF yield, 2.9% dividend while waiting. Keep it small because the next datapoint is binary.

Tranche 2 — 30%

$68

Add on a break below the $71 low, which we would expect on a weak Q3 print or a broad de-risking into it. At $68 the stock is 10.8× our FY27 EPS of $6.30 and the bear-case target is only 9% below. Skip this tranche if the Q3 print brings a third guidance cut; reassess instead.

Tranche 3 — 30%

$62 (bear target)

Only if the bear case arrives without the thesis breaking: the stock reaches $62 on multiple compression while derm share holds near 85% and the FY27 guide is flat rather than down. If the guide is down, this tranche is cancelled and the position is reviewed for exit.

1-Year Price & Key Levels